5 results match your criteria: "Centre Leon Berard and University Claude Bernard Lyon I[Affiliation]"
Safety and quality of life with maintenance olaparib plus bevacizumab in older patients with ovarian cancer: subgroup analysis of PAOLA‑1/ENGOT-ov25.
Oncologist
December 2024
Département d'Oncologie Médicale, Institut Paoli-Calmettes, Marseille, France.
Background: In PAOLA-1/ENGOT-ov25, the addition of olaparib to bevacizumab maintenance improved overall survival in patients with newly diagnosed advanced ovarian cancer. We describe the safety profile and quality of life (QoL) of this combination in older patients in PAOLA-1.
Methods: Safety (CTCAE v4.
Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma.
JCO Precis Oncol
June 2023
Hôpitaux Universitaires de Genève, Department of Clinical Pathology, Geneva, Switzerland.
Article Synopsis
- The study highlights the development of a new biomarker for Homologous Recombination Deficiency (HRD), aimed at improving patient selection for poly (ADP-ribose) polymerase (PARP) inhibitor treatments, as validated by past clinical trials.
- The new test, analyzed using data from the PAOLA-1 trial, shows promising results that surpass the Myriad myChoice Genomic Instability Score (GIS) regarding progression-free survival in treated patients.
- The findings suggest that this new test could be more effective and reliable in clinical settings, potentially benefiting more patients by providing clearer laboratory results.
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.
Lancet Oncol
August 2022
Gynecologic Oncology Group-Foundation (GOG-F), Philadelphia, PA, USA; San Francisco Medical Center, San Francisco, CA, USA.
The Gynecologic Cancer InterGroup (GCIG) sixth Ovarian Cancer Conference on Clinical Research was held virtually in October, 2021, following published consensus guidelines. The goal of the consensus meeting was to achieve harmonisation on the design elements of upcoming trials in ovarian cancer, to select important questions for future study, and to identify unmet needs. All 33 GCIG member groups participated in the development, refinement, and adoption of 20 statements within four topic groups on clinical research in ovarian cancer including first line treatment, recurrent disease, disease subgroups, and future trials.
View Article and Find Full Text PDFOlaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial.
J Gynecol Oncol
September 2021
Centre Léon BERARD and University Claude Bernard Lyon I, GINECO, Lyon, France.
Article Synopsis
- The PAOLA-1 trial studied the effects of adding maintenance olaparib to bevacizumab for patients with newly diagnosed advanced ovarian cancer, highlighting significant benefits in progression-free survival (PFS).
- This specific analysis focused on a subset of 24 Japanese patients who were randomly assigned to receive either olaparib plus bevacizumab or a placebo, showing median PFS of 27.4 months versus 19.4 months, respectively.
- The findings in the Japanese subset align with the overall PAOLA-1 trial results, confirming that the combination treatment enhances PFS in this patient population.
Getting up-to-date in the management of soft tissue sarcoma.
Future Oncol
May 2018
Department of Medical Oncology, Centre Leon Berard and University Claude Bernard Lyon I, Lyon, France.
Surgery (+ radiation therapy in selected cases) is standard treatment for adult-type localized soft tissue sarcoma (STS). Accumulating randomized clinical evidence also supports adjuvant chemotherapy as a treatment option, although this remains contentious. Doxorubicin (± ifosfamide) is the standard first-line systemic treatment for advanced STS; however, newer chemotherapeutic agents may improve outcomes achieved with single-agent doxorubicin.
View Article and Find Full Text PDF